| Product Code: ETC067169 | Publication Date: Jul 2023 | Updated Date: Aug 2025 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The liquid biopsy market in France is expected to witness significant growth over the forecast period from 2021 to 2027. This is attributed to rising cancer incidence, technological advancements in diagnostic procedures for early detection of disease, and increasing demand for personalized medicine. Additionally, favorable government initiatives and reimbursement policies are expected to drive market growth. However, limited awareness about liquid biopsy technology among healthcare professionals may hamper the growth of this market during the forecast period.
The key drivers driving the France Liquid Biopsy Market include the increasing prevalence of cancer cases in France; growing demand for personalized medicines; development & advancement of technologies related to liquid biopsies such as next-generation sequencing (NGS) and digital PCR; rising public & private funding towards research activities; availability of reimbursement policies encouraging adoption of these tests among patients; and supportive government initiatives promoting early diagnosis & treatment options for cancer patients.
Limiting factors that might hamper the market`s growth include a lack of awareness amongst physicians regarding the benefits offered by liquid biopsies and the high costs associated with technologically advanced devices used in these tests. Furthermore, stringent regulatory processes involved with product approvals also contribute negatively to its market penetration rate across various regions within France.
Some major players operating in the France Liquid Biopsy Market include Thermo Fisher Scientific Inc., QIAGEN N V., F Hoffmann-La Roche AG, Illumina Inc., Agilent Technologies Inc., Biocept Inc., SRL Diagnostics PVT Ltd.; Guardant Health Inc.; Trovagene Inc.; Menarini Silicon Biosystems Srl; Myriad Genetics INC.; Genomic Vision SA; Oxford Gene Technology Limited (OGT); Fluxion Biosciences Inc.; BioM?rieux SA; Oncomark Ltd, etc
The Covid-19 pandemic has had a negative impact on the France liquid biopsy market. The stringent government regulations imposed due to the pandemic have resulted in a decrease in demand for liquid biopsies, as well as an increase in costs related to research and development activities. In addition, many healthcare facilities have witnessed reduced patient visits, which has led to decreased revenues from diagnostic testing services. Furthermore, since clinical trials are essential for product launches of liquid biopsy products, their delay or suspension could hinder new product launches in this market over the forecast period.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 France Liquid Biopsy Market Overview |
3.1 France Country Macro Economic Indicators |
3.2 France Liquid Biopsy Market Revenues & Volume, 2020 & 2027F |
3.3 France Liquid Biopsy Market - Industry Life Cycle |
3.4 France Liquid Biopsy Market - Porter's Five Forces |
3.5 France Liquid Biopsy Market Revenues & Volume Share, By Product, 2020 & 2027F |
3.6 France Liquid Biopsy Market Revenues & Volume Share, By Application, 2020 & 2027F |
3.7 France Liquid Biopsy Market Revenues & Volume Share, By End User, 2020 & 2027F |
4 France Liquid Biopsy Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 France Liquid Biopsy Market Trends |
6 France Liquid Biopsy Market, By Types |
6.1 France Liquid Biopsy Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 France Liquid Biopsy Market Revenues & Volume, By Product, 2018 - 2027F |
6.1.3 France Liquid Biopsy Market Revenues & Volume, By Handheld Instruments, 2018 - 2027F |
6.1.4 France Liquid Biopsy Market Revenues & Volume, By Inflation Devices, 2018 - 2027F |
6.1.5 France Liquid Biopsy Market Revenues & Volume, By Guiding Devices, 2018 - 2027F |
6.1.6 France Liquid Biopsy Market Revenues & Volume, By Electrosurgical & Electrocautery Instruments, 2018 - 2027F |
6.1.7 France Liquid Biopsy Market Revenues & Volume, By Others, 2018 - 2027F |
6.2 France Liquid Biopsy Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 France Liquid Biopsy Market Revenues & Volume, By Clinical Application, 2018 - 2027F |
6.2.3 France Liquid Biopsy Market Revenues & Volume, By Non-clinical Application, 2018 - 2027F |
6.3 France Liquid Biopsy Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 France Liquid Biopsy Market Revenues & Volume, By Hospitals, 2018 - 2027F |
6.3.3 France Liquid Biopsy Market Revenues & Volume, By Academic & Research Centers, 2018 - 2027F |
6.3.4 France Liquid Biopsy Market Revenues & Volume, By Others, 2018 - 2027F |
7 France Liquid Biopsy Market Import-Export Trade Statistics |
7.1 France Liquid Biopsy Market Export to Major Countries |
7.2 France Liquid Biopsy Market Imports from Major Countries |
8 France Liquid Biopsy Market Key Performance Indicators |
9 France Liquid Biopsy Market - Opportunity Assessment |
9.1 France Liquid Biopsy Market Opportunity Assessment, By Product, 2020 & 2027F |
9.2 France Liquid Biopsy Market Opportunity Assessment, By Application, 2020 & 2027F |
9.3 France Liquid Biopsy Market Opportunity Assessment, By End User, 2020 & 2027F |
10 France Liquid Biopsy Market - Competitive Landscape |
10.1 France Liquid Biopsy Market Revenue Share, By Companies, 2020 |
10.2 France Liquid Biopsy Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here